A congenital lip pit or lip sinus is a congenital disorder characterized by the presence of pits and possibly associated fistulas in the lips. They are often hereditary, and may occur alone or in association with cleft lip and palate, termed Van der Woude syndrome. Diagnosis
Classification
They are divided into three types based on their location:
commissural pits, which are small pits near the labial commissure of the mouth,
a pit in the upper lip, in which case it may be called a midline sinus of the upper lip, and
pits in the lower lip, in which case it may be called a congenital sinus of the lower lip.In some cases commissural pits have been reported in combination with preauricaluar pits, which are near the ear. Treatment
Lip pits do not usually require any treatment, although in some reported cases surgical excision has been used or if associated with a draining sinus tract. See also
Skin dimple

References


== External links ==
Velaglucerase alfa, sold under the brand name Vpriv and manufactured by Shire plc, is a hydrolytic lysosomal glucocerebroside-specific enzyme, which is a recombinant form of glucocerebrosidase indicated as a long-term enzyme replacement therapy for those with Gaucher disease Type 1. It has an identical amino acid sequence to the naturally occurring enzyme. It was approved for use by the U.S. Food and Drug Administration (FDA) on February 26, 2010.The most common side effects include abdominal (belly) pain, headache, dizziness, bone pain, arthralgia (joint pain), back pain, infusion-related reactions, asthenia (weakness) or fatigue (tiredness), and pyrexia (fever) or increased body temperature.Velaglucerase alfa was approved for medical use in the European Union in August 2010. Medical uses
Velaglucerase alfa is indicated for long-term enzyme-replacement therapy (ERT) in people with type-1 Gaucher disease. Competitive products
Imiglucerase is Genzymes version of recombinant glucocerebrosidase. It is marketed globally under the trade name of Cerezyme. In addition, Protalix and Pfizer have received approval for marketing taliglucerase alpha in Israel, Brazil, Canada and the U.S. The companies are expected also to file for marketing authorization in Europe and elsewhere around the world. References
External links
"Velaglucerase alfa". Drug Information Portal. U.S. National Library of Medicine.